Cargando…

Effects of transcranial magnetic stimulation on anhedonia in treatment resistant major depressive disorder

BACKGROUND: Anhedonia is one of the defining features of depression but it remains difficult to target and treat. Transcranial magnetic stimulation (TMS) is a proven treatment for depression, but its effects on anhedonia and whether anhedonia can be used as a predictive biomarker of response is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Andrew M., Kang, Jee Won Diane, Gobin, Asi Polly, Tirrell, Eric, Kokdere, Fatih, Carpenter, Linda L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442591/
https://www.ncbi.nlm.nih.gov/pubmed/34453491
http://dx.doi.org/10.1002/brb3.2329
Descripción
Sumario:BACKGROUND: Anhedonia is one of the defining features of depression but it remains difficult to target and treat. Transcranial magnetic stimulation (TMS) is a proven treatment for depression, but its effects on anhedonia and whether anhedonia can be used as a predictive biomarker of response is not well known. METHODS: Snaith–Hamilton Pleasure Scale was administered to patients with depression before and after a standard course of TMS in a naturalistic outpatient setting. RESULTS: 144 patients were analyzed. There was an overall significant improvement in anhedonia from pre‐ to post‐treatment (7.69 ± 3.88 vs. 2.96 ± 3.45; p < .001). Significant correlations between improvements in anhedonia and other depressive symptoms were present (r = 0.55, p < .001). Logistic regression revealed that baseline anhedonia severity was not a significant predictor of clinical outcome. CONCLUSION: This is the first large, naturalistic study examining the effects of standard, non‐research TMS on anhedonia. Among depressed patients, TMS resulted in significant improvements in anhedonia. Patients with severe baseline anhedonia had an equal chance of achieving clinical response/remission. Patients with anhedonia should not be excluded from treatment if they are safe for outpatient care and otherwise appropriate candidates for treatment.